Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals Inc. | Nucresiran | Hereditary Transthyretin Amyloidosis with Polyneuropathy (hATTR-PN) | Phase 3 | Trial Planned | Intravenous | Genetic Disorder |
| Alnylam Pharmaceuticals Inc. | Vutrisiran - (HELIOS-A) | ATTR Amyloidosis | Phase 3 | Data Released | Subcutaneous | Genetic Disorder |
| Alnylam Pharmaceuticals Inc. | Mivelsiran - (cAPPricorn-1) | Cerebral amyloid angiopathy | Phase 2 | Ongoing | Subcutaneous | Neurology |
| Alnylam Pharmaceuticals Inc. | ALN-4324 | Type 2 diabetes | Phase 2 | Trial Planned | Intravenous | Endocrinology |
| Alnylam Pharmaceuticals Inc. | Nucresiran (ALN-TTRsc04) - (TRITON-CM) | ATTR amyloidosis | Phase 3 | Ongoing | Subcutaneous | Genetic Disorder |
| Alnylam Pharmaceuticals Inc. | Vutrisiran - (HELIOS-B) | ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) | Phase 3 | Data Released | Subcutaneous | Cardiology |
| Alnylam Pharmaceuticals Inc. | Zilebesiran - (ZENITH CVOT) | Major adverse cardiovascular (CV) events | Phase 3 | Ongoing | Subcutaneous | Cardiology |
| Alpha Tau Medical Ltd. | Alpha DaRT - (IMPACT) | Pancreatic ductal adenocarcinoma (PDAC) | Phase 3 | Intratumoral | Oncology |
